A. Jaffor Ullah

Dec 9, 2024 | onlinelibrary.wiley.com | Naeem Khan |Syed Shah |A. Jaffor Ullah |Saeed Ahmad

Dear Editors, We read with interest the article ‘An open-label, randomized trial of different re-start strategies after treatment withdrawal in HBeAg-negative chronic hepatitis B’ by Asgeir et al. [1] The study explored the hypothesis of delaying antiviral therapy restart after stopping treatment to allow for immune reconstitution leading to a higher rate of HBsAg loss. While this is a novel concept, we have questions about the patient selection and the feasibility of the study.